CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · Real-Time Price · USD
47.95
+1.95 (4.24%)
At close: Oct 24, 2024, 4:00 PM
47.61
-0.34 (-0.70%)
After-hours: Oct 24, 2024, 4:47 PM EDT
CRISPR Therapeutics AG Revenue
CRISPR Therapeutics AG had revenue of $517.00K in the quarter ending June 30, 2024, a decrease of -99.26%. This brings the company's revenue in the last twelve months to $202.23M, up 18.89% year-over-year. In the year 2023, CRISPR Therapeutics AG had annual revenue of $371.21M with 30,885.48% growth.
Revenue (ttm)
$202.23M
Revenue Growth
+18.89%
P/S Ratio
18.53
Revenue / Employee
$496,872
Employees
407
Market Cap
4.24B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 371.21M | 370.01M | 30,885.48% |
Dec 31, 2022 | 1.20M | -913.77M | -99.87% |
Dec 31, 2021 | 914.96M | 914.24M | 127,154.94% |
Dec 31, 2020 | 719.00K | -288.87M | -99.75% |
Dec 31, 2019 | 289.59M | 286.47M | 9,169.85% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Oscar Health | 7.23B |
Select Medical Holdings | 6.87B |
Surgery Partners | 2.89B |
ICU Medical | 2.30B |
Integer Holdings | 1.67B |
Haemonetics | 1.33B |
Sotera Health Company | 1.10B |
TransMedics Group | 358.76M |
CRSP News
- 18 days ago - Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma - Seeking Alpha
- 5 weeks ago - Crispr Therapeutics: Prepare To Be Bored - Seeking Alpha
- 2 months ago - Crispr's Casgevy Launch: Promising Start, Uncertain Future - Seeking Alpha
- 2 months ago - Crispr Therapeutics Q2 Earnings: Casgevy Updates Underline 'Blockbuster' Potential - Seeking Alpha
- 2 months ago - CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results - GlobeNewsWire
- 3 months ago - Crispr Therapeutics: Beaten Down But Not Broken - Seeking Alpha
- 4 months ago - CRISPR Therapeutics (CRSP) Presents at Goldman Sachs 45th Annual Global Healthcare Conference - Company Call Transcript - Seeking Alpha
- 4 months ago - Crispr Therapeutics, Futurism-Turning-Commercial, Defies 'Valuation' (Technical Analysis) - Seeking Alpha